Seeking to generate buzz around its groundbreaking AI technology for canine cancer — technology that holds promise for human applications — ImpriMed, a trailblazer in personalized pet cancer treatment predictions, selected SKC as its PR partner. The mission? To electrify ImpriMed’s Series A funding announcement and establish the company as a revolutionary force in the industry.

SKC orchestrated a strategic media campaign, securing a major feature in TechCrunch that significantly elevated the company’s industry profile. SKC also proactively pitched more than 30 media outlets across various sectors, aiming for multiple stories or mentions, and distributed the funding release via BusinessWire. The comprehensive campaign included content and message development, continuous media relations, monitoring, and reporting.

Our tenacious outreach resulted in 13 influential media hits, positioning ImpriMed as a leader in AI-driven cancer treatment. This extensive coverage included prominent outlets such as Yahoo! Finance, International Business Times, Modern Healthcare, StreetInsider, Actual News Magazine, FinSMEs, Robots.net, Tech News Tube, Upstract, and World News Era.

Through meticulous planning and execution, SKC enhanced ImpriMed’s visibility and solidified its position as a cutting-edge biotech pioneer. This successful project has since led to an ongoing partnership, with SKC continuing to deliver impactful results for ImpriMed. Together, we now have a consistent press release pipeline, fresh content, a speaking and awards program, and a proactive media program that led to more media stories that raised awareness as well as potential customers and partners for ImpriMed’s groundbreaking work in cancer treatment.

SKC's strategic expertise and unyielding commitment have proven invaluable for ImpriMed. Their PR efforts generated the crucial media hits we needed as a startup and, more importantly, brought in new customer leads. We've solidified our reputation as a pioneer in AI-driven cancer treatment recommendations. We couldn’t be more excited to continue growing together.

~ Mary Ocnean, Vice President of Commercial Operations, ImpriMed, Inc.